Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

SciClone Acquires China Rights for PAD Drug from Taiwan Liposome

publication date: Jun 26, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
SciClone Pharma, a US company that brings western-style drugs to China, has licensed exclusive rights to a treatment for peripheral arterial disease from Taiwan Liposome Company (TLC). The product, called ProFlow®, is a novel lipid formulation of prostaglandin E1 (PGE1), a vasodilator and platelet inhibitor. The agreement calls for up to $39.5 million in development and sales milestones. More details....

Stock Symbol: (NSDQ: SCLN)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...